Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose

摘要: In DTC patients, 131-radioiodine therapy has routinely been used for many years thyroid remnant ablation after surgery. To date, two different strategies can be to achieve sufficient TSH stimulation on remnant: (I) Levo-thyroxine withdrawal or (II) rhTSH stimulation. The aim of our study was compare the abdominal absorbed dose ratio between differentiated cancer patients who underwent either L-T4 We reviewed records 63 affected by cancer. All A post-therapy whole-body scan obtained 5 days therapy. Qualitative and quantitative image analysis performed. Quantitative performed drawing seven regions interest abdomen (anterior posterior views) estimate both activity (AR) (DR) in treated hypothyroidism values ratios each region (liver, stomach, ascending colon, transverse descending rectum, small intestine) were always higher than with p-values 0.000, 0.001, 0.022, 0.007, 0.002, respectively. have lower radioiodine hypothyroid patients. Our data could practical relevance terms patient management. potential impact rare radioiodine-related gastrointestinal side effects is established specifically designed prospective studies.